Fosun and Insilico Collaborate to Develop Five Candidates
publication date: Jan 13, 2022
Shanghai Fosun Pharma will collaborate with Insilico Medicine, a Hong Kong AI drug discovery company, to discover candidates for four targets. Fosun will make a $13 million upfront payment, plus potential milestones and a share of revenues from any products. It will also make an investment of unspecified size in Insilico. In addition, the two companies will co-develop Insilico's QPCTL program. QPCTL is thought to silence the “do not eat me” signal. Insilico will develop the QPCTL candidate to IND stage; Fosun will be responsible for global development. More details....
Stock Symbols: (SHA: 600196; HK: 02196)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.